IRF4 and hematopoietic and lymphoid cell neoplasm: Concurrently, a plethora of research has highlighted a consistent downregulation of IRF4 expression across the myeloid disease spectrum, encompassing acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and a range of hematopoietic cancer cell lines [23–27].